Mutation in PIGA results in a CD52-negative escape variant in a Sézary syndrome patient during alemtuzumab treatment

J Invest Dermatol. 2015 Apr;135(4):1199-1202. doi: 10.1038/jid.2014.501. Epub 2014 Nov 28.

Authors

Constantijn J M Halkes¹, Willem H Zoutman², Leslie van der Fits², Inge Jedema³, Maarten H Vermeer²

Affiliations

¹ Department of Hematology, University Medical Center Leiden, Leiden, The Netherlands. Electronic address: [email protected].
² Department of Dermatology, University Medical Center Leiden, Leiden, The Netherlands.
³ Department of Hematology, University Medical Center Leiden, Leiden, The Netherlands.

PMID: 25431852
DOI: 10.1038/jid.2014.501

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Alanine Transaminase / metabolism
Alemtuzumab
Antibodies, Monoclonal, Humanized / therapeutic use*
Antigens, CD / genetics*
Antigens, Neoplasm / genetics*
Antineoplastic Agents / therapeutic use
CD52 Antigen
Glycoproteins / genetics*
Glycosylphosphatidylinositols / chemistry
Humans
Male
Membrane Proteins / genetics*
Mutation*
Prognosis
Recurrence
Sequence Analysis, DNA
Sezary Syndrome / drug therapy*
Sezary Syndrome / genetics*
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Antigens, CD
Antigens, Neoplasm
Antineoplastic Agents
CD52 Antigen
CD52 protein, human
Glycoproteins
Glycosylphosphatidylinositols
Membrane Proteins
phosphatidylinositol glycan-class A protein
Alemtuzumab
Alanine Transaminase